Kura Oncology/KURA

$21.59

2.41%
-
1D1W1MYTD1YMAX

About Kura Oncology

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of medicines for the treatment of cancer. The Company’s pipeline consists of small molecule product candidates that target cancer signaling pathways. The Company’s products candidate includes Ziftomenib, Tipifarnib, and KO-2806. The Ziftomenib is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene for the treatment of genetically defined acute myeloid leukemia (AML) patients. Tipifarnib is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. KO-2806, is a next generation farnesyl transferase inhibitor (FTI), which it demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Ticker

KURA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Troy Wilson

Employees

142

Headquarters

San diego, United States

Kura Oncology Metrics

BasicAdvanced
$1.6B
Market cap
-
P/E ratio
-$2.08
EPS
0.86
Beta
-
Dividend rate

What the Analysts think about Kura Oncology

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 12 analysts.
40.11% upside
High $37.00
Low $21.00
$21.59
Current price
$30.25
Average price target

Kura Oncology Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-42.7M
10.62%
Profit margin
0%
-

Kura Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.13%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.50
-$0.53
-$0.50
-$0.55
-
Expected
-$0.54
-$0.55
-$0.55
-$0.55
-$0.54
Surprise
-8.07%
-3.62%
-9%
0.13%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Kura Oncology stock

Buy or sell Kura Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing